Name:
Institution:
Type:
PI
Grant Award Details
Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells.
Grant Type:
Grant Number:
DISC2-14096
Project Objective:
- To identify and test a drug candidate treatment for idiopathic pulmonary fibrosis that targets the senescent niche of lung progenitor cells
Investigator:
Disease Focus:
Lung Disease, Fibrosis
Respiratory Disorders
Human Stem Cell Use:
Adult Stem Cell
Award Value:
$1,450,876
Status:
Pre-Active
Grant Application Details
Application Title:
- Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells.
Public Abstract:
Research Objective
Novel selective pharmacological strategy targeting senescent lung stem cells
Impact
Idiopathic pulmonary fibrosis along with other interstitial and age-related lung diseases
Major Proposed Activities
- Chracterize senescence cells, including senescent stem and progenitor cells in the lung of patients affected by idiopathic pulmonary fibrosis
- Screening of a Rubedo Life Science library of senolytic small molecules prodrug on Idiopathic pulmonary fibrosis primary cells
- Development and charcterization of a humanized mouse model based on the primary IPF senescent cells characterized in Activity 1
- Pharmacological characterization of the lead senolytic compound
- Efficacy studies of the lead senolytic compound on the humanized IPF model
Statement of Benefit to California:
Progressive pulmonary fibrosis is an age-related degenerative interstitial lung disease that affects an increasing number of population in California and worldwide. The reasons of this increase include a growing aging population, decreased air quality due to increased air pollution, partially driven by climate change, and more recently by the impact of the virus SARS-CoV2 on COVID19 survivors. The proposed therapy will benefit less privileged aging populations affected by environmental hazards..
